Indivior PLC on Wednesday said the primary and secondary endpoints were not met in a trial of AEF0117 in patients with cannabis use disorder.

The Richmond, Virginia-based specialty pharmaceuticals company said the phase 2b trial was evaluating AEF0117’s efficacy and safety in treatment-seeking participants with moderate to severe cannabis use disorder.

Indivior said the trial, part of its strategic collaboration with Bordeaux, France-based biotechnology firm Aelis Farma, did not meet its primary endpoint in the proportion of people who reduced cannabis use to less than one day per week.

It also did not meet secondary endpoints in the proportion of participants who either cut their cannabis use to less than two days per week, or who transitioned to complete abstinence.

‘Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD,’ Indivior commented.

The trial had aimed to show that AEF0117 could lower cannabis use, and to determine endpoints and optimal dosage of the drug for use in future testing.

Indivior’s collaboration with Aelis includes an exclusive option for Indivior to license the global rights to AEF0117, which the firm does not currently expect to exercise.

Shares in Indivior were 2.1% lower at 894.00 pence on Wednesday afternoon in London.

Copyright 2024 Alliance News Ltd. All Rights Reserved.